Special Population Precautions for Momelotinib

Special Population Precautions for Momelotinib

Women of Childbearing Age

May cause fetal harm. Effective contraception must be used during treatment and for at least 1 week after the last dose.

Suspected or Confirmed Pregnancy

Immediately inform your doctor to assess the risks and benefits of continuing therapy, and adjust the treatment plan if necessary.

Breastfeeding Women

It is unknown whether momelotinib is excreted in human milk. Do not breastfeed during treatment and for 1 week after the last dose; discuss appropriate alternative infant feeding methods with your doctor.

Those Planning Pregnancy

It is recommended to discuss fertility planning with your doctor in advance. You may need to switch medications or arrange a washout period before attempting conception to reduce fetal exposure risk.

Drug Interactions with Momelotinib

Provide a Complete Medication List

Include prescription drugs, over‑the‑counter medications, vitamins, and herbal supplements (e.g., Chinese patent medicines, health products).

Key Points to Watch

Strong CYP3A4 inhibitors or inducers may alter the metabolic clearance rate of momelotinib.

Examples of Common Interacting Drugs

Certain antifungals (e.g., ketoconazole), antibiotics (e.g., clarithromycin), antiepileptics (e.g., carbamazepine), etc.

Management Measures

Your doctor will adjust the dose or suggest switching concomitant medications based on the interaction severity. Do not add any new drugs on your own; even over‑the‑counter cold remedies should be first reviewed with a pharmacist or physician.

Regular Review

When visiting a new specialty clinic or purchasing new medications, routinely review your medication list to ensure safety.

Mechanism of Action of Momelotinib

Janus kinases (JAKs) are intracellular signal transduction proteins that are particularly abundant in bone marrow hematopoietic stem cells.

Pathological State

In patients with myelofibrosis, mutations in bone marrow cell DNA lead to abnormally hyperactive JAK signaling pathways, triggering inflammatory responses and promoting fibrous tissue proliferation (fibrosis), which replaces normal hematopoietic tissue and reduces production of healthy blood cells.

Core Action

As a JAK inhibitor, momelotinib binds to overactive JAK proteins, blocking aberrant signal transduction and suppressing inflammation and fibrotic progression.

Clinical Benefits

It can reduce splenomegaly, improve systemic symptoms, and may restore some normal hematopoietic function.

Unique Advantage

Unlike conventional JAK inhibitors, momelotinib possesses a distinctive dual‑inhibitory property.